Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy

NCT05065970 is registered in ClinicalTrials.gov with HI-Bio, A Biogen Company as lead sponsor.

NCT NCT05065970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05065970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy
Lead sponsor
HI-Bio, A Biogen Company
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2021
Completion date
May 6, 2024
Enrollment
54 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

immunoglobulin a (iga) nephropathy